Hengrui Pharma
60027653.971.28% ( +0.68 )
Hengrui Pharma (600276)
Jiangsu Hengrui Pharmaceuticals Co.,Ltd, a pharmaceutical company, researches, develops, manufactures, and commercializes medicines to address unmet clinical ne...
- Open
- 54.00
- High
- 54.03
- Low
- 52.72
- Prev. Close
- 53.29
- Volume
- 383.05K
- Turnover
- 2.05B
- Avg Price
- 53.61
- Bid/Ask Ratio
- --
- Amplitude
- 2.46%
- 52wk High
- 73.84
- Volume Ratio
- 0.94
- Turnover Ratio
- 0.60%
Hengrui Pharma Analyst Rating
View MoreForecast & Rating
Jul 24, 2026Price forecast
¥80.3349.07%
Forecast & RatingStrong buy
19analysts
- Strong buy78.95%
- Buy21.05%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- AASTOCKS News · 1 day ago, 10:29 PM
Nomura Cuts HENGRUI PHARMA TP to HKD82.18, Lowers FY2026 Revenue and Profit Forecasts
- Tip Ranks · Jul 23 at 07:37 AM
Hengrui Wins NMPA Nod to Move Cervical Cancer Combo to First-Line Use
- PUBT · Jul 23 at 07:32 AM
Hengrui Pharma wins China approval for camrelizumab-famitinib combo as 1L cervical cancer treatment
- Tip Ranks · Jul 17 at 07:27 PM
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H (1276) Receives a Buy from Morgan Stanley
- PUBT · Jul 17 at 08:00 AM
IDEAYA shares ESMO 2026 data updates for darovasertib trials in uveal melanoma
- PUBT · Jul 16 at 05:27 AM
Hanx Biopharmaceuticals files HKEX next-day disclosure return on share repurchase cancellation
